<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-09-23T17:08:10Z</responseDate><request verb="GetRecord" identifier="oai:www.repository.cam.ac.uk:1810/318229" metadataPrefix="uketd_dc">https://api.repository.cam.ac.uk/server/oai/request</request><GetRecord><record><header><identifier>oai:www.repository.cam.ac.uk:1810/318229</identifier><datestamp>2023-12-22T13:33:00Z</datestamp><setSpec>com_1810_721</setSpec><setSpec>com_1810_256064</setSpec><setSpec>col_1810_218856</setSpec></header><metadata><uketd_dc:uketddc xmlns:uketd_dc="http://naca.central.cranfield.ac.uk/ethos-oai/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:uketdterms="http://naca.central.cranfield.ac.uk/ethos-oai/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://naca.central.cranfield.ac.uk/ethos-oai/2.0/ http://naca.central.cranfield.ac.uk/ethos-oai/2.0/uketd_dc.xsd">
   <dc:title>Biophysical approaches to characterising protein-protein interactions and intermediate species in protein aggregation</dc:title>
   <dc:identifier xsi:type="dcterms:DOI">10.17863/CAM.65349</dc:identifier>
   <dc:creator>Xu, Catherine</dc:creator>
   <uketdterms:advisor>Knowles, Tuomas</uketdterms:advisor>
   <uketdterms:advisor>Dobson, Christopher</uketdterms:advisor>
   <dcterms:abstract>The phenomenon of protein misfolding and aggregation has been associated with over 50 human diseases, including Parkinson’s disease (PD). While the hallmark deposits in aggregation-associated diseases are primarily composed of fibrillar species, intermediate oligomeric species that form during the aggregation process are believed to be a major cause of toxicity. Such species are relatively poorly characterised due to several challenges that render them inaccessible to most conventional techniques; oligomers are only present at extremely low concentrations in the aggregation reaction, and are additionally highly heterogeneous and often transient in nature. In this thesis, I present complementary approaches to address these difficulties. Firstly, an ensemble of stable, kinetically trapped oligomers with varying biophysical characteristics was established, enabling detailed structure-toxicity relationships to be investigated. Secondly, a method for the simultaneous single-molecule level characterisation and fractionation of oligomeric species under native conditions was established and applied to studying intermediate species in Parkinson’s disease-associated protein aggregation. Finally, I present a general approach to optimising experimental design, which maximises both the efficiency and information gain of experiments, and demonstrate its validation and application to several experimental systems.</dcterms:abstract>
   <uketdterms:institution>University of Cambridge</uketdterms:institution>
   <dcterms:issued>2020-09-29</dcterms:issued>
   <dc:type>Thesis</dc:type>
   <uketdterms:qualificationlevel>Doctoral</uketdterms:qualificationlevel>
   <uketdterms:qualificationname>Doctor of Philosophy (PhD)</uketdterms:qualificationname>
   <dc:language>eng</dc:language>
   <uketdterms:sponsor>Herchel Smith Fund</uketdterms:sponsor>
   <dcterms:isReferencedBy xsi:type="dcterms:URI">https://www.repository.cam.ac.uk/handle/1810/318229</dcterms:isReferencedBy>
   <dc:identifier xsi:type="dcterms:URI">https://apollo8-f-pro.lib.cam.ac.uk/bitstreams/f2829d23-f685-4475-a4cf-ae167efd5f37/download</dc:identifier>
   <uketdterms:checksum xsi:type="uketdterms:MD5">73d815a7b726419d78c4379d1574c5e7</uketdterms:checksum>
   <dcterms:license>https://apollo8-f-pro.lib.cam.ac.uk/bitstreams/14d3dc54-efd7-4541-be62-5d4d0dd8a420/download</dcterms:license>
   <uketdterms:checksum xsi:type="uketdterms:MD5">353adac0d1ebdfd65ab16480263c3c87</uketdterms:checksum>
   <dc:rights>https://www.rioxx.net/licenses/all-rights-reserved/</dc:rights>
   <dc:subject>Protein aggregation</dc:subject>
   <dc:subject>Amyloid</dc:subject>
   <dc:subject>Oligomers</dc:subject>
   <dc:subject>Alpha-synuclein</dc:subject>
   <dc:subject>Microfluidics</dc:subject>
</uketd_dc:uketddc>
</metadata></record></GetRecord></OAI-PMH>